Vaccine therapy in NHL: future promises and current limitations
Vaccine therapy in NHL: future promises and current limitations
Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding VH and VL genes as single-chain Fv (scFv), which has been fused to Fragment C (FrC) of tetanus toxin to enhance recognition and response. The fusion gene induces strong anti-idiotypic protection against lymphoma in experimental models, and is now in clinical trials with encouraging results emerging. This principle of fusing a pathogen-derived sequence is widely applicable. A coat protein from a potato virus substituted for the FrC sequence has also been found to be capable of promoting anti-tumor immunity. The current design is effective in inducing anti-idiotypic (Id) antibody and CD4+ T-cell attack. For intracellular tumor antigens expressed as MHC Class I-associated peptides, a design consisting of a gene encoding a single domain of FrC linked to a candidate peptide sequence has been developed. This induces fast cytotoxic T-cell attack on peptide-expressing tumor cells. Injection of DNA appears safe and clinical trials will test the efficacy of this approach, and probably lead to improvements in these flexible vaccines.
non-Hodgkin's lymphoma, DNA vaccines, tetanus toxin, B-lymphocytes
S85-S90
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
King, A.
460f716f-e5d7-4962-83a8-6c5c04bd067a
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
2003
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
King, A.
460f716f-e5d7-4962-83a8-6c5c04bd067a
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
Stevenson, F.K., King, A. and Ottensmeier, C.H.
(2003)
Vaccine therapy in NHL: future promises and current limitations.
Leukemia and Lymphoma, 44 (Supplement 3), .
(doi:10.1080/10428190310001623711).
Abstract
Recent advances in genomics are revealing new molecular targets for vaccination strategies in cancer, and unraveling the immune pathways that must be activated. Initially, work focused on idiotypic antigen expressed by the clonal immunoglobulin (Ig) of B-cell tumors. This involved assembling the encoding VH and VL genes as single-chain Fv (scFv), which has been fused to Fragment C (FrC) of tetanus toxin to enhance recognition and response. The fusion gene induces strong anti-idiotypic protection against lymphoma in experimental models, and is now in clinical trials with encouraging results emerging. This principle of fusing a pathogen-derived sequence is widely applicable. A coat protein from a potato virus substituted for the FrC sequence has also been found to be capable of promoting anti-tumor immunity. The current design is effective in inducing anti-idiotypic (Id) antibody and CD4+ T-cell attack. For intracellular tumor antigens expressed as MHC Class I-associated peptides, a design consisting of a gene encoding a single domain of FrC linked to a candidate peptide sequence has been developed. This induces fast cytotoxic T-cell attack on peptide-expressing tumor cells. Injection of DNA appears safe and clinical trials will test the efficacy of this approach, and probably lead to improvements in these flexible vaccines.
This record has no associated files available for download.
More information
Published date: 2003
Keywords:
non-Hodgkin's lymphoma, DNA vaccines, tetanus toxin, B-lymphocytes
Identifiers
Local EPrints ID: 26615
URI: http://eprints.soton.ac.uk/id/eprint/26615
ISSN: 1042-8194
PURE UUID: f123cdfb-6868-49b8-9619-1a0a117a6bfb
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 16 Mar 2024 02:54
Export record
Altmetrics
Contributors
Author:
A. King
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
